Skip to main content
Shenzhen Bioeasy Biotechnology Co., Ltd. logo

Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 300942 ISIN · CNE100004C78 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 910 across all filing types
Latest filing 2026-06-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300942

About Shenzhen Bioeasy Biotechnology Co., Ltd.

https://www.bioeasy.com

Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.

Recent filings

Filing Released Lang Actions
关于不向下修正“易瑞转债”转股价格的公告
Capital/Financing Update Classification · 85% confidence The document is a formal announcement by Shenzhen Yirui Biotechnology Co., Ltd regarding its decision not to downward adjust the conversion price of its existing convertible bonds (“Yirui Convertible Bonds”). It outlines bond issuance details, adjustment triggers, board resolutions, and future adjustment rights. This constitutes an update on the company’s capital structure and financing terms rather than a full report or simple publication notice. It therefore fits the Capital/Financing Update category.
2026-06-04 Chinese
第三届董事会第十六次会议决议公告
Regulatory Filings Classification · 75% confidence The document is a formal announcement of board resolutions by the company’s board of directors (third board, 16th meeting) concerning convertible bond conversion price adjustments. It does not report a change in board or senior management (so not MANG), nor is it a shareholder vote result (DVA) or any other specific report type. It is a standard regulatory announcement of board decisions, making it a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-06-04 Chinese
关于“易瑞转债“恢复转股的公告
Share Issue/Capital Change Classification · 65% confidence The document is a formal corporate announcement by Shenzhen Yirui Biotechnology Co., Ltd. concerning the resumption of conversion rights for its convertible bonds (“易瑞转债”), specifying bond codes, suspension and resumption dates. This is an update on capital structure (convertible bond conversion), fitting the “Share Issue/Capital Change” category.
2026-06-02 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司向不特定对象发行可转换公司债券2026年度第一次临时受托管理事务报告
Capital/Financing Update Classification · 82% confidence The document is a detailed trustee management report by Dongxing Securities on Shenzhen Yirui Biotech’s issuance of convertible corporate bonds, covering bond terms, issuance scale, conversion mechanics, trustee duties, profit distribution and subsequent price adjustments. It is not merely an announcement or certification, but a comprehensive update on the company’s financing activity (the bond issuance and its ongoing management). This fits the Capital/Financing Update category.
2026-05-28 Chinese
关于“易瑞转债”预计触发转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 84% confidence The document is a public announcement (“提示性公告”) by the company concerning anticipated triggering of the downward adjustment condition for its listed convertible bond (“易瑞转债”). It details bond issuance background, listing particulars, and the mechanics and thresholds for conversion‐price reset. This is not a financial report (10‐K or IR), not an AGM/EGM results or proxy material, not a director’s dealing, nor an interest‐rate notice; rather it is an update on a financing instrument and related capital structure. Therefore it falls under “Capital/Financing Update” (CAP).
2026-05-28 Chinese
2025年度权益分派实施公告
Notice of Dividend Amount Classification · 90% confidence The document is a corporate stock exchange announcement detailing the company’s 2025 profit distribution plan (cash dividend per 10 shares), record and ex-dividend dates, dividend payment mechanics, and related adjustments. This matches a Notice of Dividend Amount rather than an annual report, interim report, or any other category.
2026-05-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.